M
Melissa Alsina
Researcher at University of South Florida
Publications - 53
Citations - 6280
Melissa Alsina is an academic researcher from University of South Florida. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 25, co-authored 53 publications receiving 5920 citations. Previous affiliations of Melissa Alsina include Ohio State University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel,Thomas Martin,Michael Wang,Ravi Vij,Andrzej Jakubowiak,Sagar Lonial,Suzanne Trudel,Vishal Kukreti,Nizar J. Bahlis,Melissa Alsina,Asher Chanan-Khan,Francis K. Buadi,Frederic J. Reu,George Somlo,Jeffrey A. Zonder,Kevin W. Song,A. Keith Stewart,Edward A. Stadtmauer,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,Sundar Jagannath +22 more
TL;DR: Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.
Journal ArticleDOI
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson,Hannah R. Briemberg,Sundar Jagannath,Patrick Y. Wen,Bart Barlogie,James R. Berenson,Seema Singhal,David S. Siegel,David Irwin,Michael W. Schuster,Gordan Srkalovic,Raymond Alexanian,S. Vincent Rajkumar,Steven A. Limentani,Melissa Alsina,Robert Z. Orlowski,Kevin Najarian,Dixie Lee Esseltine,Kenneth C. Anderson,Anthony A. Amato +19 more
TL;DR: Bortezomib-associated peripheral neuropathy seemed reversible in the majority of patients after dose reduction or discontinuation, and the overall occurrence was independent of baseline neuropathy or type of prior therapy.
Journal ArticleDOI
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
TL;DR: This is a first report demonstrating that Notch-1 signaling may be a primary mechanism mediating the BMS influence on hematologic malignant cell growth and survival.
Journal ArticleDOI
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij,Michael Wang,Jonathan L. Kaufman,Sagar Lonial,Andrzej Jakubowiak,A. Keith Stewart,Vishal Kukreti,Sundar Jagannath,Kevin T. McDonagh,Melissa Alsina,Nizar J. Bahlis,Frederic J. Reu,Nashat Gabrail,Andrew R. Belch,Jeffrey Matous,Peter P. Lee,Peter Rosen,Michael Sebag,David H. Vesole,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,David S. Siegel +23 more
TL;DR: The results of the present study support the use of carfilzomib in R/R MM patients with relapsed and/or refractory multiple myeloma.